TwinStrand Biosciences, Inc. v. Guardant Health, Inc.

CourtDistrict Court, D. Delaware
DecidedJanuary 31, 2023
Docket1:21-cv-01126
StatusUnknown

This text of TwinStrand Biosciences, Inc. v. Guardant Health, Inc. (TwinStrand Biosciences, Inc. v. Guardant Health, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
TwinStrand Biosciences, Inc. v. Guardant Health, Inc., (D. Del. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE TWINSTRAND BIOSCIENCES, INC. & ) UNIVERSITY OF WASHINGTON, ) Plaintiffs and Counterclaim Defendants, ) Vv. Civil Action No. 21-1126-GBW-SRF GUARDANT HEALTH, INC., Defendant and Counterclaim Plaintiff. )

MEMORANDUM ORDER AMENDING CASE SCHEDULE At Wilmington this 31st day of January, 2023, the court having considered the emergency motion to extend the case schedule filed by defendant Guardant Health, Inc. (“Defendant”) (D.I. 214), and the response of plaintiffs Twinstrand Biosciences, Inc. and University of Washington (“Plaintiffs”) (D.I. 218), IT IS ORDERED that the emergency motion is GRANTED-IN-PART as follows: 1. Applications for amendments to the scheduling order are governed by Rule 16(b)(4), which provides that “[a] schedule may be modified only for good cause and with the judge’s consent.” Fed. R. Civ. P. 16(b)(4). “Good cause is present when the schedule cannot be met despite the moving party’s diligence.” Meda Pharm. Inc. v. Teva Pharm. USA, Inc., C.A. No. 15-785-LPS, 2016 WL 6693113, at *1 (D. Del. Nov. 14, 2016). 2. Here, good cause exists for an extension that will give both sides an opportunity to complete the depositions of party and third-party witnesses. Defendant has shown that the case has largely remained on schedule since the entry of the original scheduling order more than a year ago, despite a subsequent expansion of the asserted claims and patents in the case. (D.I. 20;

D.I. 30) Yet correspondence between the parties confirms that both sides will need to take depositions after the fact discovery deadline expires on February 3, 2023. (See, e.g., D.I. 214, Ex. A; D.L 218, Ex. C at 1) 3. The parties agree that an extension of the fact discovery deadline is necessary to accommodate the remaining individual, corporate, and third-party depositions. (D.I. 214 at □ 20; D.I. 218 at 6) The focus of the dispute is on how much additional time is needed. Defendant proposes extending the fact discovery deadline by about two months, necessitating a corresponding one-month extension of the expert discovery deadlines. (D.I. 214, Proposed Order) Plaintiffs counter that a one-month extension of the fact discovery deadline is sufficient, and the expert discovery deadlines should remain in place. (D.I. 218, Appendix A) 4. Based on a review of the record, the court finds that a one-month extension of the fact discovery deadline, and corresponding extensions of the deadlines for final contentions, is sufficient to accommodate the remaining fact discovery. Defendant alludes to brewing discovery disputes affecting the scope of 30(b)(6) depositions and argues that it cannot complete deposition discovery before February 17. (D.I. 214 at 20) A March 3 deadline for fact discovery provides sufficient additional time for the parties to resolve their disputes and go forward with the remaining depositions. To ensure an efficient process going forward, on or before February 3, 2023, the parties shall exchange proposals for scheduling depositions of the remaining fact witnesses. 5. Defendant requests an additional two months of fact discovery to avoid the expense and resources of deposition-related activities while the court considers its pending motion to stay. (D.I. 214 at 29; D.I. 209) The benefit of this delay will not accrue unless the court grants the motion to stay, which is speculative at this stage. The record shows that Defendant’s motion

to stay is based on the institution of infer partes review proceedings on only two of the eight patents-in-suit. (D.I. 210 at 3; DI. 218, Ex. D) 6. For the foregoing reasons, the case schedule at D.I. 20 is amended as follows: Event Current Deadline (D.I. 20 | Extended deadline unless otherwise noted) Step | case narrowing Jan. 30, 2023 (D.L. 137) Feb. 3, 2023 Feb. 3, 2023 Mar. 3, 2023 Feb. 10, 2023 Mar. 10, 2023 Step 2 case narrowing Feb. 13, 2023 (D.I. 137) Final infringement contentions Feb. 17, 2023 Mar. 3, 2023 Feb. 17, 2023 (D.I. 137) __| Mar. 3, 2023 Final invalidity contentions Mar. 3, 2023 Mar. 10, 2023 Mar. 3, 2023 (D.I. 137 Mar. 10, 2023 Mar. 24, 2023 Rebuttal expert reports Apr. 21, 2023 Reply expert reports May 15, 2023 Dispositive and Daubert motions Jun. 23, 2023 Hearing on dispositive and Daubert | Vacated (D.I. 49; Apr.12 | TBD motions 2022 Oral Order) — Previously Jul. 25, 2023 Sept. 13, 2023 (D.L. 137) Sept. 27, 2023 (D.L 137) Oct. 20, 2023 Oct. 27, 2023, 9:00 a.m. Nov. 6, 2023 7. This Memorandum Order is filed pursuant to 28 U.S.C. § 636(b)(1)(A), Fed. R. Civ. P. 72(a), and D. Del. LR 72.1(a)(2). The parties may serve and file specific written objections within fourteen (14) days after being served with a copy of this Memorandum Order. Fed. R. Civ. P. 72(a). The objections and responses to the objections are limited to two (2) pages each.

8. The parties are directed to the court’s Standing Order For Objections Filed Under Fed. R. Civ. P. 72, dated March 7, 2022, a copy of which is available on the court’s website, www.ded.uscourts. gov.

herry R. United, States Magistrate Judge

4 *

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
TwinStrand Biosciences, Inc. v. Guardant Health, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/twinstrand-biosciences-inc-v-guardant-health-inc-ded-2023.